Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 2b dose‑ranging study of rodatristat ethyl in pulmonary arterial hypertension
2020-004971-42Phase 2Terminated
- Sponsor
- Altavant Sciences
- Start
- Apr 2021
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial in pulmonary arterial hypertension (PAH) comparing Rodatristat ethyl dose-ranging with Placebo (2 arms). Primary endpoint: Percent change from baseline to 24 weeks of pulmonary vascular resistance. Started Apr 2021; status: terminated.
02
Drugs
rodatristat
03
Conditions
pulmonary arterial hypertension (PAH)
Beyond the preview
Go deeper on 2020-004971-42.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2020-004971-42.